β-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: A companion analysis of the TAX 324 trial

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6222-6228

  Cullen, Kevin J ^a   Schumaker, Lisa ^a   Nikitakis, Nikolaos ^a   Goloubeva, Olga ^a   Tan, Ming ^a   Sarlis, Nicholas J ^a   Haddad, Robert I ^a   Posner, Marshall R ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETA TUBULIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE TRANSFERASE P1; PROTEIN BCL 2; PROTEIN P53; THYMIDYLATE SYNTHASE; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; TAXOID; TUBULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INDUCTION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; REPRODUCIBILITY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 74949095969     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.0953     Document Type: Article

References (35)

1. American Cancer Society: Cancer Facts & Figures 2008. Atlanta, GA, American Cancer Society, 2008
2. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology V. 1.2007. www.nccn.org
3. Laimer K, Spizzo G, Gastl G, et al: High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. Oral Oncol 43:193-198, 2007
4. Chin D, Boyle GM, Williams RM, et al: Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113:789-797, 2005
5. Salesiotis A, Cullen KJ: Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: Evolution of a model beyond TNM staging. Curr Opin Oncol 12:229-239, 2000
6. Yu Z, Weinberger PM, Haffty BG, et al: Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 11:1160-1166, 2005
7. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T: Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: A potential marker for prognosis. Clin Cancer Res 10: 3110-3116, 2004
8. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008
9. Sampaio-Goes FC, Oliveira DT, Dorta RG, et al: Expression of PCNA, p53, Bax, and Bcl-X in oral poorly differentiated and basaloid squamous cell carcinoma: Relationships with prognosis. Head Neck 27:982-989, 2005
10. Lim SC, Zhang S, Ishii G, et al: Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 10:166-172, 2004
11. Geisler SA, Olshan AF, Weissler MC, et al: P16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8:3445-3453, 2002
12. Schumaker L, Nikitakis N, Goloubeva O, et al: Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res 14:5877-5883, 2008
13. Nishimura T, Newkirk K, Rasmussen A, et al: Glutathione s-transferase expression predicts response to cisplatin-based chemotherapy in head and neck cancer. Clinical Cancer Res 2:1859-1865, 1996
14. Cullen KJ, Newkirk KA, Schumaker LM, et al: Glutathione-S-transferase p amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63:8097-8102, 2003
15. Shiga H, Heath EI, Rasmussen AA, Trock B, et al: Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5:4097-4104, 1999
16. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
17. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
18. Tian G-L, Tang ML, Fang H-B, et al: Efficient methods for estimating constrained parameters with applications to regularized (lasso) logistic regression. Computational Statistics and Data Analysis 52:3528-3542, 2008
19. McKean PG, Vaughan S, Gull K: The extended tubulin superfamily. J Cell Sci 114:2723-2733, 2001
20. Khodiyar VK, Maltais LJ, Sneddon KM, et al: A revised nomenclature for the human and rodent alphatubulin gene family. Genomics 90:285-289, 2007
21. Ferrandina G, Zannoni GF, Martinelli E, et al: Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12:2774-2779, 2006
22. Mozzetti S, Ferlini C, Concolino P, et al: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11:298-305, 2005
23. Paradiso A, Mangia A, Chiriatti A, et al: Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16: iv14-iv19, 2005 (suppl 4)
24. Urano N, Fujiwara Y, Doki Y, et al: Clinical significance of class III beta-tubulin expression and its predictivevalueforresistancetodocetaxel- basedchemotherapy in gastric cancer. Int J Oncol 28:375-381, 2006
25. Seve P, Mackey J, Isaac S, et al: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-2007, 2005
26. Seve P, Isaac S, Tredan O, et al: Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481-5486, 2005
27. Seve P, Lai R, Ding K, et al: Class III betatubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of NCIC JBR. 10. Clin Cancer Res 13:994-999, 2007
28. Dozier JH, Hiser L, Davis JA, et al: Beta class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res 5:R157-R169, 2003
29. Yang Z, Schumaker L, Egorin M, et al: Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis. Clin Cancer Res 12:5817-5825, 2006
30. Rostovtseva TK, Bezrukov SM: VDAC regulation: Role of cytosolic proteins and mitochondrial lipids. J Bioenerg Biomembr 40:163-170, 2008
31. Rostovtseva TK, Sheldon KL, Hassanzadeh E, et al: Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respiration. Proc Natl Acad Sci USA 105:18746-18751, 2008
32. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733, 1993
33. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
34. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
35. Pena JC, Thompson CB, Recant W, et al: Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 85:164-170, 1999